Diabeter Nederland B.V.
- Address
- Blaak 6, 3011 TA Rotterdam, The Netherlands
Diabeter Nederland B.V. - Type 1 Diabetes Research Center
Diabeter Nederland B.V. is a specialized research center dedicated to advancing therapeutic interventions for Type 1 Diabetes (T1D). The center focuses on innovative approaches aimed at preserving beta cell function and modulating immune responses in patients with recently diagnosed Type 1 Diabetes, with particular emphasis on adolescent and young adult populations.
- Immunomodulatory therapies including teplizumab and Diamyd (GAD65 antigen-based treatment) for preserving insulin production
- Tolerogenic dendritic cell therapy for immune regulation in Type 1 Diabetes
- Beta cell preservation strategies and glycemic control interventions in early-stage disease
The center conducts phase 1b and advanced clinical trials investigating both safety and immunological effectiveness of novel therapeutic approaches. Research protocols specifically target patients aged 1 to 25 years with Stage 3 Type 1 Diabetes, including those carrying specific HLA DR3-DQ2 haplotypes and GAD65 antibodies. The center's comprehensive approach encompasses evaluation of prandial insulin independency, beta cell function preservation, and long-term glycemic control outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diabeter Nederland B.V.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Teplizumab Versus Placebo in Stage 3 Type 1 Diabetes Patients Aged 1-25: A Randomized, Double-Blind, Phase 3 Trial | Sanofi-Aventis Recherche & Developpement | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Colecalciferol | 1 | Unknown | 2022-03-17 | 2022-03-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.